In this regard, targeted NEU1 inhibition could address multiple aspects of AD pathology, combining anti-inflammatory effects with a potential reduction in amyloid-beta burden through modulation of APP metabolism and sialylation status [57,107,168]. Here, APP is linked to Alzheimer disease.